PT - JOURNAL ARTICLE AU - Siddharth Pattnaik AU - Dipankar Das AU - Varun Akur Venkatesan TI - An AI-based quantitative home-use framework for assessing fertility and identifying novel hormone trends by recording urine hormones AID - 10.1101/2021.05.11.21257023 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.11.21257023 4099 - http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257023.short 4100 - http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257023.full AB - Background Fertility testing using urinary hormones has been used to improve the likelihood of pregnancy effectively. To provide fertility scores, the existing home-use systems measure one or two hormones. However, the hormone profiles vary depending on cycle duration, fertility-related disorders, drugs and other treatments. Here we introduce Inito, a mobile-phone connected reader that is scalable to multiple hormone tests. In this report, we assess the accuracy of the quantitative home-based fertility monitor, Inito Fertility Monitor (IFM), and suggest using IFM as a device to monitor and analyse female hormone patterns. We further show that Inito can be used as a tool to decipher novel hormone patterns in a more profound way than the existing knowledge in the field.Methods There were two aspects to our analysis: i. Evaluation of Inito Fertility Monitor efficiency characteristics for urinary Estrone-3-glucuronide (E3G), Pregnanediol glucuronide (PdG) and Luteinizing hormone (LH) assessment, and ii. A retrospective study of patients’ hormone profiles using IFM. For the performance assessment, the recovery percentage of the three hormones from IFM was evaluated using standard spiked solutions, the reproducibility of re-prediction and the correlation between re-predicted values from IFM and ELISA. The first urine sample of the day was collected from 100 women who volunteered for the study and IFM was provided to 52 more women to use it at home to track their fertile days.Finding We observed that with all three hormones, IFM had an accurate recovery percentage and had a CV of less than 10 percent for separate test strips through tests of the same dosage making it a reliable tool to monitor hormone patterns of patients. Furthermore, in predicting the concentration of E3G, PdG and LH in urine samples, we show that IFM has a high correlation with ELISA. We show that certain hormone trends associated with urinary E3G, PdG and LH could be accurately captured using IFM. In addition, we report a novel criterion for earlier confirmation of ovulation compared to existing criteria. Finally, we present a novel hormone pattern associated with most of the menstrual cycles by examining hormone profiles from the volunteers recruited for the clinical trial.Interpretation The Inito Fertility Monitor is an effective tool for calculating the urinary concentrations of E3G, PdG and LH and can also be used to provide accurate fertility scores and confirm ovulation. In addition, the sensitivity of IFM facilitates the monitoring of menstrual cycle-related hormone patterns, therefore also making it a great tool for physicians to track the hormones of their patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN15534557Funding StatementThe study has been conducted and funded by Samplytics Technologies Pvt. Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB - Sparsh Hospital BangaloreAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is available in the manuscript. Any additional data will be made available upon inquiry.